Cost-effectiveness of tissue-type plasminogen activator in the 3-to 4.5-hour time window for acute ischemic stroke

Stroke

Volumn 42, Issue 8, 2011, Pages 2257-2262

  Tung, Christie E ^a   Win, Sandra S ^a   Lansberg, Maarten G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cost effectiveness; quality adjusted life year; stroke; tissue type plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

AGED; ANALYSIS OF VARIANCE; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CALCULATION; CASE REPORT; CHRONOTHERAPY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECISION THEORY; DECISION TREE; DRUG COST; HEALTH CARE COST; HIDDEN MARKOV MODEL; HOSPITALIZATION COST; HOUR TIME WINDOW; HUMAN; MALE; MEDICARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANKIN SCALE; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

BRAIN ISCHEMIA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FIBRINOLYTIC AGENTS; HEALTH CARE COSTS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 79961209792     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.615682     Document Type: Article

References (17)

1. Demaerschalk BM, Hwang HM, Leung G. Cost analysis review of stroke centers, telestroke, and rt-PA. Am J Manag Care. 2010;16:537-544.
2. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Al e. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke: NINDS rt-PA stroke study group. Neurology. 1998;50: 883-890. (Pubitemid 28212810)
3. Johnston S. The economic case for new stroke thrombolytics. Stroke. 2010;4:S59-S62.
4. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
5. Young KC, Benesch CG, Jahromi BS. Cost-effectiveness of multimodal CT for evaluating acute stroke. Neurology. 2010;75:1678-1685.
6. Reed SD, Blough DK, Meyer K, Jarvik JG. Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals. Neurology. 2001;57:305-314. (Pubitemid 32667366)
7. Earnshaw SR, Jackson D, Farkouh R, Schwamm L. Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis. Stroke. 2009;40:1710-1720.
8. Chambers MG, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value Health. 2002;5:82-97. (Pubitemid 34274866)
9. Samsa GP, Reutter RA, Parmigiani G, Ancukiewicz M, Abrahamse P, Lipscomb J. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J Clin Epidemiol. 1999;52:259-271. (Pubitemid 29148438)
10. Hirsch JA, Yoo AJ, Nogueira RG, Verduzco LA, Schwamm LH, Pryor JC. Case volumes of intra-arterial and intravenous treatment of ischemic stroke in the USA. J NeuroIntervent Surg. 2009;1:27-31.
11. Gold M, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
12. Arias E. United States life tables, 2006. Natl Vital Stat Rep. 2010; 58:1-40.
13. Rawlins M. National institute for clinical excellence and its value judgments. BMJ. 2004;329:224-227. (Pubitemid 39013284)
14. Ehlers L, Anderson G, Clausen LB, Bech M, Kjolby M. Costeffectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke. 2007;38:85-89. (Pubitemid 46035611)
15. Demaerschalk BM, Hwang HM, Leung G. US cost burden of ischemic stroke: a systematic literature review. Am J Manag Care. 2010;16: 525-533.
16. Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? a systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2010;102:82-88.
17. Suh WW, Hillner BE, Pierce LJ, Hayman JA. Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys. 2005;61:1054-1061. (Pubitemid 40340899)